## The "No Ligand Depletion" Assumption Is Unnecessary and Can Be Misleading

#### Gilles Gnacadja

AMGEN Thousand Oaks, California, USA


Discovery on Target, 2013 GPCR-Based Drug Discovery

Boston, Massachusetts, USA 24-25 September 2013


- Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix

- 1 Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix

#### My Initiation Problem: A "Bumpy" Response Curve




Sigmoid response curves are expected and what usual formulas give.




"Bumpy" response curves can occur and cannot be simulated with usual formulas.

#### Solving the "Bump Problem"

## Solved the actual math problem, not a convenient substitute.





Developed and developing methods and algorithms to


- Simulate and explain bumpy response;
- Simulate responses (sigmoid or not), without manual derivation of formulas and assumptions this requires.



25 September 2013

- Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix

#### Current Practices — Illustrated with Trivial Receptor-Ligand Interaction



$$R + L \rightleftharpoons RL$$


#### "No Ligand Depletion" assumed

$$[R]_{ ext{Total}} \ll [L]_{ ext{Total}}$$
  $[L]_{ ext{Equil}} = [L]_{ ext{Total}}$   $ho = rac{[RL]_{ ext{Equil}}}{[R]_{ ext{Total}}} = rac{[L]_{ ext{Total}}}{K_{ ext{d.apparent}}} = K_{ ext{d.apparent}}$ 

#### "No Ligand Depletion" not assumed

$$ho = rac{oxed{[RL]_{Equil}}}{oxed{[R]_{Total}}} = \cdots$$
 $oldsymbol{K_{d,apparent}} = oldsymbol{K_{d}} + rac{oxed{[R]_{Total}}}{2}$ 

### More Examples



- $[R]_{Total} \ll [L]_{Total}$  is not mathematically sound. Operational wisdom:  $[R]_{Total} < 10\%$  of  $[L]_{Total}$ .
- Not always applicable experimentally, e.g. in miniaturized assays.
- Need not be applicable in vivo.
- New formula derivation needed for every new biochemical interaction system.
- Only possible with "receptor-centric" models.
   (Unique species in role of receptor contained in all complex species.)



- $[R]_{Total} \ll [L]_{Total}$  is not mathematically sound. Operational wisdom:  $[R]_{Total} < 10\%$  of  $[L]_{Total}$ .
- Not always applicable experimentally, e.g. in miniaturized assays.
- Need not be applicable in vivo.
- New formula derivation needed for every new biochemical interaction system.
- Only possible with "receptor-centric" models.
   (Unique species in role of receptor contained in all complex species.)



- $[R]_{Total} \ll [L]_{Total}$  is not mathematically sound. Operational wisdom:  $[R]_{Total} < 10\%$  of  $[L]_{Total}$ .
- Not always applicable experimentally, e.g. in miniaturized assays.
- Need not be applicable in vivo.
- New formula derivation needed for every new biochemical interaction system.
- Only possible with "receptor-centric" models.
   (Unique species in role of receptor contained in all complex species.)



- $[R]_{Total} \ll [L]_{Total}$  is not mathematically sound. Operational wisdom:  $[R]_{Total} < 10\%$  of  $[L]_{Total}$ .
- Not always applicable experimentally, e.g. in miniaturized assays.
- Need not be applicable in vivo.
- New formula derivation needed for every new biochemical interaction system.
- Only possible with "receptor-centric" models.
   (Unique species in role of receptor contained in all complex species.)

- $[R]_{Total} \ll [L]_{Total}$  is not mathematically sound. Operational wisdom:  $[R]_{Total} < 10\%$  of  $[L]_{Total}$ .
- Not always applicable experimentally, e.g. in miniaturized assays.
- Need not be applicable in vivo.
- New formula derivation needed for every new biochemical interaction system.
- Only possible with "receptor-centric" models.
   (Unique species in role of receptor contained in all complex species.)



- Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- 2 Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix

The "Bump Problem", or how I became involved The "No Ligand Depletion" Assumption Prior Work

# "No Ligand Depletion" Assumption Discarded for Competitive Antagonism

$$R + A \rightleftharpoons RA$$
 $+$ 
 $B$ 
 $\downarrow$ 
 $RB$ 

Miniaturized Receptor Binding Assays: Complications Arising from Ligand Depletion Clare M. Scaramellini Carter, Juliet R. Leighton-Davies and Steven J. Charlton J Biomol Screen 2007: 12: 255 originally oublished online Jan 26. 2007



The "Bump Problem", or how I became involved The "No Ligand Depletion" Assumption Prior Work

## "No Ligand Depletion" Assumption Partially Discarded for Allosteric Modulation

$$R + A \rightleftharpoons RA$$

$$+ \qquad +$$

$$B \qquad B$$

$$\parallel \qquad \parallel$$

$$RB + A \rightleftharpoons RAB$$

"No Ligand Depletion" discarded for A, maintained for B  $[B]_{\text{Fouil}} = [B]_{\text{Total}}$ 

0022-38680840203-027-034820.00
The Journal of Phaskacococy and Experimental Therapeutics
Copyright O 1066 by The American Society for Pharmacology and Experimental Therapeutics

JURY 2007-94, 2007


The Allosteric Radioligand Depletion on the Quantification of Allosteric Modulator Interactions


Vinesh A, Aylani, David J, McLoughlin, Patrick M, Sexton, and Arthur Christopoulos



- Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix







R: Receptor

L: Ligand

A: Antagonist


*T* : Trap

25 September 2013

- Actually solving the math problem gives the "bump" feature.
- Solving the usual substitute only gives sigmoid curves.

- 1 Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix





"No Ligand Depletion" not assumed  $[R]_T = 2 pM$ 

The "No Ligand Depletion" method can be substantially inaccurate.

- 1 Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix



#### Summary

#### **Calculating Equilibrium in Receptor Pharmacology**

- Customary methods
  - Assume "No Ligand Depletion"
  - Manually derive explicit formulas
  - Reduced accuracy
  - Typically sigmoid curves
- Developed and developing better methods
  - Mathematics and algorithms to actually solve equations for equilibrium



- 1 Typical: Convenient Assumptions and Manual Derivations
  - The "Bump Problem", or how I became involved
  - The "No Ligand Depletion" Assumption
  - Prior Work
- Better: Algorithms Two Use Cases
  - Receptor-Ligand-Antagonist-Trap Model
  - Allosteric Ternary Complex Model
- Wrapping up
  - Summary
  - Appendix



## More Shots at the "No Ligand Depletion" Assumption

Biochimica et Biophysica Acta, 632 (1980) 464—469 © Elsevier/North-Holland Biomedical Press

COMPETITIVE BINDING STUDIES WITH MULTIPLE SITES EFFECTS ARISING FROM DEPLETION OF THE FREE RADIOLIGAND

J.W. WELLS, N.J.M. BIRDSALL, A.S.V. BURGEN and E.C. HULME

coss-secv./rr/cesses cress: 00,00
Copyright O by The American Society for Pharmacology and Experimental Theraporation of International Company of the Compan

Ligand Dissociation Constants From Competition Binding Assays: Errors Associated with Ligand Depletion

Proc. Natl. Acad. Sci. USA Vol. 84, pp. 6654-6658, October 1987

An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves ANNON HOROUTZ AND ALEXANDER LEVITZEE.

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS Vol. 284, No. 1, January, pp. 26-29, 1991

A Simple Method for Calculating the Dissociation Constant of a Receptor (or Enzyme) · Unlabeled Ligand Complex from Radioligand

Displacement Measurements

Robert L. Martin, Franco Renosto, and Irwin H. Segel

0028-895X765061197-0122-000 Copyright © by The American Society for Pharmanology and Experimental Therapeutics

Interpretation of Binding Curves Obtained with High Receptor Concentrations: Practical Aid for Computer Analysis STEPPANE SMILES

Miniaturized Receptor Binding Assays: Complications Arising from Ligand Depletion Clare M. Scaramellini Carter, Julier R. Leighton-Davies and Steven J. Charton J. Biomol Screen 2007; 12; 255 originally published online Jan 26, 2007

0022-036506/2233-027-032\$20.00 The Journal or Passasconor are Environmental Treasure Connight C 2008 by The American Society for Pharmacolog

The Impact of Orthosteric Radioligand Depletion on the Quantification of Allosteric Modulator Interactions (Imesh A. Ayani, David J. McLouchlin, Patrick M. Sexton, and Arthur Christopoulos

0098-00X06/2093-318--726890.00 Mountain Planaroctory Copyright O 2006 The American Society for Pharmacology and Experimental Therapouti

Cell-Based and Biochemical Structure-Activity Analyses of Analogs of the Microtubule Stabilizer Dictyostatin Brianne S. Raccor, Andreas Vogt, Rachel P. Sikorski, Charitha Madiraju,

Raghavan Balachandran, Kia Montgomery, Youseung Shin, Yoshikazu Fukui, Won-Hyuk Jung, Dennis P. Curran, and Billy W. Day

Description of the Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D<sub>2</sub> and D<sub>3</sub> donamine receptors

Juan Zhen, Tamara Antonio, Aloke K. Dutta, Maarten E.A. Reith

←□ ト ←□ ト ← 亘 ト ← 亘 ・ 夕 へ ○

Polynomial System for Equilibrium State (with Association Constants)

$$H + L \Longrightarrow HL$$
 $+ + +$ 
 $A + T \Longrightarrow AT$ 
 $\parallel \qquad \parallel$ 
 $RA \qquad LT$ 

$$[R] + K_{RL}[R][L] + K_{RA}[R][A] = [R]_{Total}$$
  
 $[L] + K_{RL}[R][L] + K_{LT}[L][T] = [L]_{Total}$   
 $[T] + K_{AT}[A][T] + K_{LT}[L][T] = [T]_{Total}$   
 $[A] + K_{AT}[A][T] + K_{RA}[R][A] = [A]_{Total}$ 

Polynomial System for Equilibrium State, Reformulated as a Fixed-Point Equation

$$[R] = \frac{[R]_{Total}}{1 + K_{RL}[L] + K_{RA}[A]}$$

$$+ \quad + \quad +$$

$$A + T \implies AT$$

$$[L] = \frac{[L]_{Total}}{1 + K_{RL}[R] + K_{LT}[T]}$$

$$[T] = \frac{[T]_{Total}}{1 + K_{AT}[A] + K_{LT}[L]}$$

$$[A] = \frac{[A]_{Total}}{1 + K_{AT}[T] + K_{RA}[R]}$$


#### Verboten


 $[L] = [L]_{Total}$  and  $[A] = [A]_{Total}$  in right-hand side of equations



25 September 2013

Polynomial System for Equilibrium State, Solved by Fixed-Point Iterations





#### Gory details



#### ScienceDirect Journal of Theoretical Biology 244 (2007) 478-488

Journal of Theoretical Biology

Monotonicity of interleukin-1 receptor-ligand binding with respect to antagonist in the presence of decoy receptor

David Balaban , Mark Durst , Chris Vezina , Yu Li

Gilles Gnacadja , Alex Shoshitaishvili , Michael J. Gresser , Brian Varnum ,

#### Gorier details

MATHEMATICAL METHODS IN THE APPLIED SCIENCES Math. Meth. Appl. Sci. 2007; 30:201-211 Published online 23 October 2006 in Wiley InterScience (www.interscience.wilev.com) DOI: 10.1002/mma.782 MOS subject classification: 47 H10: 74 G25: 74 G30: 74 G15: 92 C40



Fixed points of order-reversing maps in  $\mathbb{R}^n$ and chemical equilibrium Gilles Gnacadja

4 D > 4 B > 4 B > 4 B

Polynomial System for Equilibrium State (with Association Constants)

$$[R] + K_{RA}[R][A] + K_{RB}[R][B] + \alpha K_{RA}K_{RB}[R][A][B] = [R]_{Total}$$

$$[A] + K_{RA}[R][A] + \alpha K_{RA}K_{RB}[R][A][B] = [A]_{Total}$$

$$[B] + K_{RB}[R][B] + \alpha K_{RA}K_{RB}[R][A][B] = [B]_{Total}$$

- 4 ロ ト 4 個 ト 4 重 ト 4 重 ト 9 Q CP


Polynomial System for Equilibrium State, Reformulated as a Fixed-Point Equation

#### Verboten

$$[A] = [A]_{Total}$$
 and  $[B] = [B]_{Total}$  in right-hand side of equations



Polynomial System for Equilibrium State, Solved by Special Reduction





Method not fully an instance of approach advocated:



"No Ligand Depletion" assumption eliminated;




Manual labor changed, not eliminated (but done once and for all);



ATCM pervasive, could not await comprehensive algorithm.



#### Usual Method Can Be Substantially Inaccurate



Pharmacology = Pharmacokinetics (PK) + Pharmacodynamics (PD) Applicable math: dynamical systems (differential equations), etc.

Discovery-stage Receptor Pharmacology is neither PK nor PD.

Pharmacology = "Pharmacostatics" (PS) + PK + PD

Applicable math: **polynomial equations**, dynamical systems, etc.

Customary practice is to derive explicit formulas at all cost:

Manual labor for every new model

Reduced accuracy

Typically sigmoidal response curves:

Sometimes models are simply abandoned

Relevant polynomial equations possess nice distinctive mathematical properties. Developed and developing algorithms to actually solve them with a priori assurance of success.

Pharmacology = Pharmacokinetics (PK) + Pharmacodynamics (PD) Applicable math: dynamical systems (differential equations), etc. Discovery-stage Receptor Pharmacology is neither PK nor PD.

Pharmacology = "Pharmacostatics" (PS) + PK + PD
Applicable math: polynomial equations, dynamical systems, etc.

Customary practice is to derive explicit formulas at all cost:

Manual labor for every new models

Reduced accuracy

Typically sigmoidal response curves;

Sometimes models are simply abandoned

Relevant polynomial equations possess nice distinctive mathematical properties. Developed and developing algorithms to actually solve them with a priori assurance of success.

Pharmacology = Pharmacokinetics (PK) + Pharmacodynamics (PD) Applicable math: dynamical systems (differential equations), etc. Discovery-stage Receptor Pharmacology is neither PK nor PD.

Pharmacology = "Pharmacostatics" (PS) + PK + PD
Applicable math: polynomial equations, dynamical systems, etc.

Customary practice is to derive explicit formulas at all cost:

Manual labor for every new model;

Reduced accuracy

Typically sigmoidal response curves;

Sometimes models are simply abandoned

Relevant polynomial equations possess nice distinctive mathematical properties. Developed and developing algorithms to actually solve them with a priori assurance of success.

Pharmacology = Pharmacokinetics (PK) + Pharmacodynamics (PD) Applicable math: dynamical systems (differential equations), etc. Discovery-stage Receptor Pharmacology is neither PK nor PD.

Pharmacology = "Pharmacostatics" (PS) + PK + PD
Applicable math: polynomial equations, dynamical systems, etc.

Customary practice is to derive explicit formulas at all cost:

Manual labor for every new model;

Reduced accuracy;

Typically sigmoidal response curves;

Sometimes models are simply abandoned.

Relevant polynomial equations possess nice distinctive mathematical properties. Developed and developing algorithms to actually solve them with a priori assurance of success.

Pharmacology = Pharmacokinetics (PK) + Pharmacodynamics (PD) Applicable math: dynamical systems (differential equations), etc. Discovery-stage Receptor Pharmacology is neither PK nor PD.

Pharmacology = "Pharmacostatics" (PS) + PK + PD
Applicable math: polynomial equations, dynamical systems, etc.

Customary practice is to derive explicit formulas at all cost:

Manual labor for every new model;

Reduced accuracy;

Typically sigmoidal response curves;

Sometimes models are simply abandoned.

Relevant polynomial equations possess nice distinctive mathematical properties. Developed and developing algorithms to actually solve them with a priori assurance of success.

Pharmacology = Pharmacokinetics (PK) + Pharmacodynamics (PD) Applicable math: dynamical systems (differential equations), etc. Discovery-stage Receptor Pharmacology is neither PK nor PD.

Pharmacology = "Pharmacostatics" (PS) + PK + PD
Applicable math: polynomial equations, dynamical systems, etc.

Customary practice is to derive explicit formulas at all cost:

Manual labor for every new model;

Reduced accuracy;

Typically sigmoidal response curves;

Sometimes models are simply abandoned.

Relevant polynomial equations possess nice distinctive mathematical properties. Developed and developing algorithms to actually solve them with a priori assurance of success.